Oxidation, Inflammation, ApoE and Coronavirus, Oh My!

There are now evidence-based strategies for improving clinical outcomes in COVID-19. Recommendations are based on the phases of the disease because optimal interventions for one phase may not be appropriate for a different phase. The four phases addressed in the lecture are Prevention, Infection, Inflammation and Recovery.

Emerging evidence show two different components of pathophysiology of COVID-19, early infection, and late stage severe complications. These two aspects of the disease suggest two different patterns of clinical emphasis. In the lecture we will examine tactics that address four main stages of disease progression for COVID-19.

SARS-CoV-2 virus may both evade the innate immune response and kill macrophages (white blood cells). One clinical strategy involves supporting patient innate and adaptive immune responses early in the time course of illness.

At the other end of the COVID-19 disease pathology spectrum is the risk of fatality driven by excessive and persistent upregulation of inflammatory mechanisms associated with a cytokine (inflammatory mediator) storm. The second clinical strategy is to prevent or mitigate excessive inflammatory response to prevent the cytokine storm associated with high mortality risk.

Clinical support for immune system pathogen clearance mechanisms involves the activation of immune response components that are inherently inflammatory. This puts the goals of the first clinical strategy (immune activation) potentially at odds with the goals of the second strategy (slowing or stopping proinflammatory effects). This creates a need for discernment about the time course of the illness and with that, understanding of which components of an overall strategy to apply at each phase of the time course of the illness.

In this webinar, "Oxidation, Inflammation, ApoE4 and Coronavirus, Oh My!!" we will review evidence from early observational studies and the existing literature on both outcomes and mechanisms of disease, to inform a phased approach to support the patient at risk for infection, with infection, with escalating inflammation during infection, and at risk of negative sequelae as they move into recovery. We will also discuss measuring lab markers such as ApoE, Essential Fatty Acids, Oxidized LDL, SpectraCell intracellular antioxidant levels, and fasting Insulin so as to understand our underlying susceptibility to illness.

Cost: $20